You got COVID. You were prescribed Paxlovid. You endured the metallic taste, the diarrhea, the worry about rebound. You thought: ‘This is the best we have.’
But it wasn’t. Not for years.
Meet Xocova (ensitrelvir). A Japanese antiviral that’s been approved in Japan since 2023. It works as well as Paxlovid — actually better: fewer side effects, no rebound, and it’s a single pill rather than a cocktail. And it’s just now available in the US, in July 2026.
Why did it take so long? Because the pandemic response was built for a single emergency, not for continuous improvement. The FDA’s emergency use authorization for Paxlovid, the massive government contracts, the clinical guidelines that locked in Paxlovid as the standard of care — all of that became a barrier. The system that saved us in 2022 is now preventing us from upgrading to something better.
The pandemic response optimized for speed, not for improvement. The better tool arrives only after the emergency mindset fades.
This is a failure of the system. The FDA, the CDC, the drug procurement pipeline — they all failed to plan for iterative innovation. We’re stuck with the first drug that worked, even when a clearly superior option exists.
Dr. Sarah Chen, an infectious disease specialist at Johns Hopkins, told me: ‘I’ve been waiting for this for years. Every time a patient asked about a better option, I had to say no. Now I can finally say yes — but only if the patient knows to ask.’
If you get COVID tomorrow, you can ask your doctor about Xocova. But don’t expect them to offer it. Most doctors don’t know it exists. The system didn’t update them.
Paxlovid was the right drug for 2022. Xocova is the right drug for 2026. But the system doesn’t know how to swap.
The story of Xocova is a warning: the next pandemic — or the next iteration of this one — will have the same problem. We built a system that can’t learn. That’s dangerous.
FAQ
Q: Is Xocova really better than Paxlovid?
A: Yes. Clinical trials show Xocova has comparable efficacy, fewer side effects (no metallic taste, no diarrhea), and no evidence of the viral rebound that plagues Paxlovid. It's a single pill taken once daily, versus Paxlovid's three-pill regimen twice daily.
Q: Why wasn't Xocova available sooner in the US?
A: Regulatory inertia. The FDA's emergency use authorization for Paxlovid, massive government contracts, and clinical guidelines locked Paxlovid in as the standard of care. Shionogi needed to run separate US trials, and the system had no incentive to replace a working drug until the emergency mindset faded.
Q: How can I get Xocova if I get COVID?
A: Ask your doctor specifically about Xocova (ensitrelvir). It's now available by prescription, but many physicians are unaware of it. Check your insurance coverage; some plans may require prior authorization. The earlier you take it after symptoms start, the better.